Skip to main content

Advertisement

Log in

Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database

  • Pharmacoepidemiology and Prescription
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor, is widely used in association with standard chemotherapy in metastatic cancer. Well tolerated, bevacizumab is sometimes associated with serious adverse drug reactions (ADRs). The objective of this study is to describe the profile of ADRs related to bevacizumab and reported to the French Pharmacovigilance system.

Method

All serious cases of ADRs associated with bevacizumab recorded in the French Pharmacovigilance database up to November 31, 2010 were identified and analyzed, focusing on patient information, drug exposure, and characteristics of the ADRs. Categorical variables were compared using the chi-square test when appropriate.

Results

A total of 351 serious cases involving 626 ADRs were recorded in the database during the study interval. The most frequent ADRs reported involved the gastrointestinal system (21.9%). The most frequent ADRs included gastrointestinal perforation (4.8%), thromboembolic events (4.0%), pulmonary embolism (3.2%), hypertension (2.7%), gastrointestinal hemorrhage (2.7%), and cerebral hemorrhage or vascular accident (2.6%). The median duration of bevacizumab exposure was four cycles (range 1–30) when ADRs occurred. In 18 cases of death directly caused by ADRs, 50% occurred after only one cycle. In cases of disability, 40% of ADRs were neurologic: neuropathy, paralysis, and paresis.

Conclusion

To the best of our knowledge, this is the first analysis of bevacizumab safety profile using data collected in a national pharmacovigilance database. Our study confirms the frequency and seriousness of gastrointestinal, thromboembolic, and hemorrhage events with bevacizumab use and provides a picture of the bevacizumab safety profile in daily medical practice, despite intrinsic limitations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Reference

  1. Shih T, Lindley C (2006) Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28(11):1779–1802

    Article  PubMed  CAS  Google Scholar 

  2. European Medicines Agency. Avastin EPAR—Product information. Available at: www.ema.europa.eu

  3. Arrêté du 28 avril 2005 relatif aux Bonnes Pratiques de Pharmacovigilance. French Official Journal (2005) 9087–9102

  4. Edwards I, Aronson J (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255–1260

    Article  PubMed  CAS  Google Scholar 

  5. Begaud B, Evreux JC, Jouglard J, Lagier G (1985) Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie 40:111–118

    PubMed  CAS  Google Scholar 

  6. Begaud B, Martin K, Haramburu F, Moore N (2002) Rates of spontaneous reporting of adverse drug reactions in France. JAMA 288:1588

    Article  PubMed  Google Scholar 

  7. Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96(12):1788–1795

    Article  PubMed  CAS  Google Scholar 

  8. Miles D (2008) Management of toxicity in patients receiving therapy with bevacizumab. Eur J Cancer Suppl 6(6):29–39

    Article  CAS  Google Scholar 

  9. Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10:559–568

    Article  PubMed  CAS  Google Scholar 

  10. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300(19):2277–2285

    Article  PubMed  CAS  Google Scholar 

  11. Elice F, Rodegjiero F (2010) Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact. Thromb Res Suppl 125(2):S55–S57

    Article  Google Scholar 

  12. European Medicines Agency (2010). European Medicines Agency completes its review of Avastin used in breast cancer. News and press release archive, December 16, 2010. Available at: www.ema.europa.eu.

  13. Food and Drug Administration (2010). FDA begins process to remove breast cancer indication from Avastin label. FDA News release, December 16, 2010. Available at: www.fda.gouv

Download references

Conflict of interest

None.

Financial support

None.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Solène Taugourdeau-Raymond.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Taugourdeau-Raymond, S., Rouby, F., Default, A. et al. Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database. Eur J Clin Pharmacol 68, 1103–1107 (2012). https://doi.org/10.1007/s00228-012-1232-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-012-1232-7

Keywords:

Navigation